Drug Profile
Coacillium - Legacy Healthcare
Alternative Names: Coacillium cutaneous solution - Legacy Healthcare; Coacillium oral solution - Legacy Healthcare; Coacillium topical solution - Legacy Healthcare; Coacillium®; LH-8; LH8 - Legacy Healthcare; Topical Coacillium 21%Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Legacy Healthcare
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
- Mechanism of Action E selectin expression inhibitors; Intercellular adhesion molecule-1 expression inhibitors; Interleukin-8 expression inhibitors; Ki-67 antigen expression stimulants; Proto oncogene protein c bcl 2 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Alopecia areata
- Clinical Phase Unknown Alopecia
- Preclinical Fatigue
- Research Atopic dermatitis; Psoriasis
Most Recent Events
- 12 Mar 2024 Clinical trials in Alopecia (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)
- 12 Mar 2024 Early research in Atopic dermatitis in Switzerland (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)
- 12 Mar 2024 Early research in Psoriasis in Switzerland (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)